MMSI Merit Medical Systems (MMSI) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0000856982
Cluster · 5 insidersC-suite buying · 5Form 144 · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $1.1M priced
What the filings say about MMSI
Insiders, 180 days
-$2.2M net sold
5 buyers · 2 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-09-25
Planned sales (Form 144), 90 days
$2.5M
2 notices
Merit Medical Systems insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, MERIT MEDICAL SYSTEMS INC insiders sold a net $2.2M of stock across 76 Form 4 purchases and sales, with 5 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 4, 2026.
- The trade is 41.5% of the 18,051 shares held after it.
- No other insider sold within 30 days.
Insider activity: CHIEF OPERATING OFFICER Peterson Neil W. sold about $678.4K of MMSI on Aug 24, 2026.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jan 6, 2026.
- The trade is 83.9% of the 25,551 shares held after it.
- No other insider sold within 30 days.
Insider activity: CHIEF OPERATING OFFICER Peterson Neil W. sold about $1.8M of MMSI on Aug 4, 2026.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 73.2% of the 2,220 shares held after it.
- 4 other insiders bought within 30 days.
Insider activity: Chief Commercial Officer Smith Christian Adam bought about $99.2K of MMSI on May 11, 2026; 4 other insiders bought within 30 days.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 22, 2025.
- The trade is 64.0% of the 7,809 shares held after it.
- No other insider sold within 30 days.
Insider activity: Director Ward Lynne N. sold about $313.1K of MMSI on May 7, 2026.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Mar 5, 2025.
- The trade is 100.0% of the 2,000 shares held after it.
- 4 other insiders bought within 30 days.
Insider activity: CHIEF LEGAL OFFICER, SECRETARY Lloyd Brian G. bought about $125.3K of MMSI on May 7, 2026; 4 other insiders bought within 30 days.76 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$2.2M over 180 days
-$2.5M over 90 days
below 70% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+11.8% year over year
more than 54% of Medical Devices
Margin
8.5% net margin
more than 79% of Medical Devices
Buybacks
no share repurchases reported
Short interest
6.5% of the float short (float per yahoo 2026-10-27) · 6.0 days to cover · settled 2026-10-15
more than 73% of Medical Devices
The situation: each line is one rule over one dataset
3 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 5 in the prior 90
Why it matters
The absence is the signal: 5 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch MMSI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+13.0%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MMSI: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in MMSI
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-09-25 · disclosed 27 days later
$1,001 - $15,000
Bought 2025-07-22 · disclosed 22 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MMSI planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
NEIL W PETERSON
Filed 2026-08-24
$678.4K
NEIL W PETERSON
Filed 2026-08-04
$1.8M
Clinical pipeline
16 registered trials, 8 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
16
Not applicable
8 active
What changed recently
Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP)
2026-10-10 · Completion moved 2026-04-15 → 2026-05-06
,
Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)
2026-10-08 · Completion moved 2026-06 → 2027-06
,
PREEMIE: Study for Treatment of PDA in Premature Infants
2026-10-08 · Completion moved 2026-08 → 2026-11
Not applicable
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Merit Medical Systems Inc Employee Good Governance Pac
Cycle 2026 · $11K spent
$34.2K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Fred P.Lampropoulos
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$10.4M
$16.4M
$3.2M
+74%
-1%
2023
$10.1M
$9.8M
$2.7M
+37%
-14%
2022
$8.1M
$12.1M
$2.1M
+27%
-20%
2021
$7.5M
$10.7M
$1.7M
+12%
+15%
2020
$7.7M
$12.6M
$1.7M
+78%
+47%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
5 insiders reported buying shares.
The record shows a net $2.2M sold by insiders over 180 days, $2.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
MMSI financials
Revenue growth
+11.8%
XBRL, annual
Net margin
8.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.6B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MMSI
| FY Dec 2025 | $1.5B |
| FY Dec 2024 | $1.4B |
| FY Dec 2023 | $1.3B |
| FY Dec 2022 | $1.2B |
| FY Dec 2021 | $1.1B |
| Jun 2026 | $418.8M |
| Mar 2026 | $381.9M |
| Dec 2025 | $393.9M |
| Sep 2025 | $384.2M |
| Jun 2025 | $382.5M |
| Mar 2025 | $355.4M |
| Dec 2024 | $355.2M |
| Sep 2024 | $339.8M |
At each fiscal year end
Single quarter
Net margin, TTM
+9.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM MMSI
| FY Dec 2025 | +8.5% |
| FY Dec 2024 | +8.9% |
| FY Dec 2023 | +7.5% |
| FY Dec 2022 | +6.5% |
| FY Dec 2021 | +4.5% |
| Jun 2026 | +9.3% |
| Mar 2026 | +10.7% |
| Dec 2025 | +9.6% |
| Sep 2025 | +7.2% |
| Jun 2025 | +8.5% |
| Mar 2025 | +8.5% |
| Dec 2024 | +7.9% |
| Sep 2024 | +8.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$203.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM MMSI
| FY Dec 2025 | $215.7M |
| FY Dec 2024 | $185.7M |
| FY Dec 2023 | $110.9M |
| FY Dec 2022 | $69.3M |
| FY Dec 2021 | $119.3M |
| Jun 2026 | $51.9M |
| Mar 2026 | $24.7M |
| Dec 2025 | $74.0M |
| Sep 2025 | $52.5M |
| Jun 2025 | $69.6M |
| Mar 2025 | $19.5M |
| Dec 2024 | $65.3M |
| Sep 2024 | $38.0M |
At each fiscal year end
Single quarter
Debt to equity
0.44x
long-term 2026-06-30 plus current 2023-09-30 (33 months older than the period end); equity 2026-06-30
Debt to equity MMSI
| FY Dec 2025 | 0.47x |
| FY Dec 2024 | 0.53x |
| FY Dec 2023 | 0.69x |
| FY Dec 2022 | 0.17x |
| FY Dec 2021 | 0.23x |
| Jun 2026 | 0.44x |
| Mar 2026 | 0.45x |
| Dec 2025 | 0.47x |
| Sep 2025 | 0.48x |
| Jun 2025 | 0.49x |
| Mar 2025 | 0.51x |
| Dec 2024 | 0.53x |
| Sep 2024 | 0.57x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.38x
TTM operating cash flow over long-term 2026-06-30 plus current 2023-09-30 (33 months older than the period end)
Cash flow to debt MMSI
| FY Dec 2025 | 0.40x |
| FY Dec 2024 | 0.30x |
| FY Dec 2023 | 0.18x |
| FY Dec 2022 | 0.58x |
| FY Dec 2021 | 0.61x |
| Jun 2026 | 0.38x |
| Mar 2026 | 0.40x |
| Dec 2025 | 0.40x |
| Sep 2025 | 0.36x |
| Jun 2025 | 0.33x |
| Mar 2025 | 0.31x |
| Dec 2024 | 0.30x |
| Sep 2024 | 0.28x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+9.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity MMSI
| FY Dec 2025 | +8.7% |
| FY Dec 2024 | +9.3% |
| FY Dec 2023 | +8.0% |
| FY Dec 2022 | +6.8% |
| FY Dec 2021 | +4.8% |
| Jun 2026 | +9.2% |
| Mar 2026 | +9.1% |
| Dec 2025 | +8.7% |
| Sep 2025 | +8.3% |
| Jun 2025 | +8.6% |
| Mar 2025 | +9.2% |
| Dec 2024 | +9.3% |
| Sep 2024 | +9.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+5.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets MMSI
| FY Dec 2025 | +5.0% |
| FY Dec 2024 | +5.1% |
| FY Dec 2023 | +4.7% |
| FY Dec 2022 | +4.5% |
| FY Dec 2021 | +2.9% |
| Jun 2026 | +5.3% |
| Mar 2026 | +5.4% |
| Dec 2025 | +5.0% |
| Sep 2025 | +4.7% |
| Jun 2025 | +4.8% |
| Mar 2025 | +5.1% |
| Dec 2024 | +5.1% |
| Sep 2024 | +5.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+7.8%
operating income after a 25.1% effective tax rate, over long-term 2026-06-30 plus current 2023-09-30 (33 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital MMSI
| FY Dec 2025 | +7.7% |
| FY Dec 2024 | +8.1% |
| FY Dec 2023 | +6.2% |
| FY Dec 2022 | +6.4% |
| FY Dec 2021 | +4.6% |
| Jun 2026 | +7.8% |
| Mar 2026 | +7.7% |
| Dec 2025 | +7.7% |
| Sep 2025 | +7.6% |
| Jun 2025 | +7.8% |
| Mar 2025 | +8.1% |
| Dec 2024 | +8.1% |
| Sep 2024 | +7.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+8.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed MMSI
| FY Dec 2025 | +7.9% |
| FY Dec 2024 | +7.2% |
| FY Dec 2023 | +7.0% |
| FY Dec 2022 | +6.1% |
| FY Dec 2021 | +4.2% |
| Jun 2026 | +8.1% |
| Mar 2026 | +7.9% |
| Dec 2025 | +7.9% |
| Sep 2025 | +7.3% |
| Jun 2025 | +7.1% |
| Mar 2025 | +7.3% |
| Dec 2024 | +7.2% |
| Sep 2024 | +8.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
38.77x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing MMSI
| FY Dec 2025 | 41.38x |
| FY Dec 2024 | 47.65x |
| FY Dec 2023 | 46.60x |
| FY Dec 2022 | 54.32x |
| FY Dec 2021 | 74.17x |
| Jun 2026 | 28.53x |
| Mar 2026 | 29.71x |
| Dec 2025 | 41.38x |
| Sep 2025 | 42.68x |
| Jun 2025 | 47.45x |
| Mar 2025 | 51.82x |
| Dec 2024 | 47.65x |
| Sep 2024 | 48.21x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$5.9B
market value at close 2026-10-26 on 2026-07-28 shares, plus long-term 2026-06-30 plus current 2023-09-30 (33 months older than the period end), minus cash 2026-06-30
Enterprise value MMSI
| FY Dec 2025 | $5.5B |
| FY Dec 2024 | $6.0B |
| FY Dec 2023 | $4.6B |
| FY Dec 2022 | $4.2B |
| FY Dec 2021 | $3.7B |
| Jun 2026 | $4.4B |
| Mar 2026 | $4.3B |
| Dec 2025 | $5.5B |
| Sep 2025 | $5.3B |
| Jun 2025 | $5.9B |
| Mar 2025 | $6.6B |
| Dec 2024 | $6.0B |
| Sep 2024 | $6.0B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield MMSI
| FY Dec 2025 | +4.1% |
| FY Dec 2024 | +3.3% |
| FY Dec 2023 | +2.5% |
| FY Dec 2022 | +1.7% |
| FY Dec 2021 | +3.4% |
| Jun 2026 | +4.9% |
| Mar 2026 | +5.4% |
| Dec 2025 | +4.1% |
| Sep 2025 | +4.2% |
| Jun 2025 | +3.5% |
| Mar 2025 | +2.9% |
| Dec 2024 | +3.3% |
| Sep 2024 | +3.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
1.66x
P/E over trailing EPS growth of 23%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing MMSI
| FY Dec 2025 | 8.40x |
| FY Dec 2024 | 1.94x |
| FY Dec 2023 | 1.84x |
| FY Dec 2022 | 0.99x |
| FY Dec 2021 | n/a |
| Jun 2026 | 1.22x |
| Mar 2026 | 2.16x |
| Dec 2025 | 8.40x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | 3.13x |
| Dec 2024 | 1.94x |
| Sep 2024 | 2.61x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.5B | $1.4B | $1.3B | $1.2B |
| Gross profit | $738.3M | $643.3M | $583.9M | $519.1M |
| Operating income | $184.7M | $155.7M | $123.9M | $87.6M |
| Net income | $128.5M | $120.4M | $94.4M | $74.5M |
| EPS (diluted) | 2.13 | 2.03 | 1.62 | 1.29 |
| Operating cash flow | $297.4M | $220.8M | $145.2M | $114.3M |
| Cash | $446.4M | $376.7M | $587.0M | $58.4M |
| Long-term debt | $734.0M | $729.6M | $823.0M | $186.8M |
SEC XBRL, fiscal years, as known on 2026-10-28
MMSI Stock Sonar score 6/7 axes
Find similar shapesCompareMMSI ranks highest on profitability (68th percentile) and insider conviction (61st), and lowest on institutional and government (12th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MMSI filings, in plain words
Are Merit Medical Systems insiders buying or selling MMSI?
In the 180 days to 2026-10-28, Merit Medical Systems insiders were net sellers, a net $2.2M: $573.3K of purchases and $2.8M of sales reported on Form 4, by 5 buyers and 2 sellers.
Have members of Congress traded MMSI?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by Lisa McClain dated 2025-09-25.
Are there planned insider sales of MMSI?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $2.5M of stock; the latest, by NEIL W PETERSON, was filed 2026-08-24.
Read the full summary
In the 180 days to 2026-10-28, Merit Medical Systems insiders were net sellers of MMSI, a net $2.2M across purchases and sales reported on Form 4 by 5 buyers and 2 sellers. 5 insiders reported purchases in that window. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Members of Congress have disclosed trades in MMSI, none in the last year; the latest on record is a sale by Lisa McClain dated 2025-09-25. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $2.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
